logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Pemigatinib for locally advanced or metastatic, relapsed or refractory cholangiocarcinoma with FGFR2 fusion or rearrangement

< Back

Pemigatinib for locally advanced or metastatic, relapsed or refractory cholangiocarcinoma with FGFR2 fusion or rearrangement

Drugs

Cancer and Palliative Care

December 2019


Pemigatinib is in clinical development for adults with locally advanced or metastatic bile duct cancer (cholangiocarcinoma) with FGFR2 fusion or rearrangement who have failed previous treatment. Advanced cholangiocarcinoma begins in the bile duct but spreads to other parts of the body and often is not diagnosed until a late stage. Symptoms of cholangiocarcinoma include yellowing of the skin and whites of eyes (jaundice), itchy skin, dark urine, loss of appetite, persistent tiredness, abdominal pain, fever, chills and shivering. The causes of cholangiocarcinoma are not yet fully understood but include smoking, obesity and alcohol consumption.
Pemigatinib is administered orally and it works by blocking receptors (targets) called fibroblast growth factor receptor (FGFR). FGFRs are found in many cancer cells and play a key role in the growth and spread of the cancer cells. By blocking the FGFR, pemigatinib is expected to reduce the growth and spread of the cancer. If licensed, pemigatinib may offer an additional treatment option for patients with locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement who have failed previous therapy.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts